Nucleic acid extraction device, nucleic acid analysis device equipped with nucleic acid extraction device, and nucleic acid extraction method

The nucleic acid extraction device addresses the challenge of obtaining pure nucleic acid solutions by employing a chamber design with a controlled magnetic bead positioning system, ensuring high purity and accuracy in nucleic acid analysis.

JP2024158670APending Publication Date: 2024-11-08TOYO KOHAN CO LTD +1

Patent Information

Application Number
JP2023074036
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing systems face difficulties in obtaining highly pure nucleic acid solutions during extraction from cells using magnetic beads, as they do not effectively control the shape of microchannels and positioning of magnetic beads, leading to impurities and inefficiencies.

Method used

A nucleic acid extraction device with a chamber design having an inlet higher than the outlet, a tapered shape, and a magnetic bead control unit that positions magnetic beads at a tapered section within the chamber, allowing for controlled stirring and elution of nucleic acids while minimizing contamination.

Benefits of technology

The device achieves highly pure nucleic acid solutions by effectively separating and eluting nucleic acids from cells using magnetic beads, reducing impurities and enabling accurate nucleic acid analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024158670000001_ABST
    Figure 2024158670000001_ABST
Patent Text Reader

Abstract

To collect a high-purity nucleic acid solution by using magnetic beads.SOLUTION: According to the present invention, an eluate is supplied into a chamber having a tapered part. In a state where the magnetic beads are magnetically collected in the tapered part, the eluate is collected.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a nucleic acid extraction device that extracts nucleic acid from a biological sample such as cells, a nucleic acid analyzer that is provided with the nucleic acid extraction device and analyzes the extracted nucleic acid, and a nucleic acid extraction method that extracts nucleic acid from a biological sample such as cells. [Background technology]

[0002] Causative and marker gene mutations have been identified in various diseases including cancer. Gene mutations related to cancer prognosis prediction and drug side effects have also been identified. For example, single nucleotide variants (SNV) and single nucleotide polymorphisms (SNP) are typical examples of such gene mutations.

[0003] As one system for detecting such gene mutations, a system using a DNA chip (also called a DNA microarray) is known. The DNA chip has a configuration in which nucleic acid probes (a wild-type probe corresponding to the wild type and a mutant probe corresponding to the mutant type) corresponding to the gene mutation to be detected are fixed to a substrate. Using genomic DNA collected from a subject as a template, a nucleic acid amplification reaction is carried out using a pair of primer sets that sandwich a region containing the gene mutation to be detected, thereby obtaining a labeled nucleic acid fragment. A solution containing the obtained nucleic acid fragment is brought into contact with the DNA chip under specified reaction conditions. If the solution contains a nucleic acid fragment containing a gene mutation, a signal from the mutant probe can be detected.

[0004] Based on the above-mentioned basic principle, the presence or absence of genetic mutations in the genomic DNA of a subject can be examined. Note that genetic mutations are not limited to SNVs and SNPs, and DNA chips having nucleic acid probes corresponding to sequences are also used in microsatellite, DNA methylation, and chimera gene testing.

[0005] Incidentally, although not limited to a system for detecting gene mutations using a DNA chip, a nucleic acid analysis technique such as the system first includes a step of extracting nucleic acid from cells or tissues to be analyzed. A method for extracting nucleic acid from cells is known as a magnetic bead method. In the magnetic bead method, nucleic acid contained in a solution in which cells or the like are disrupted is adsorbed onto magnetic beads, the magnetic beads are separated from the solution by magnetic force, and then the nucleic acid adsorbed onto the magnetic beads is eluted.

[0006] Furthermore, although not limited to a system that detects gene mutations using a DNA chip, a nucleic acid analysis technique such as this system can be realized as a microchannel device as disclosed in Patent Document 1. A microchannel device is a device having a microchannel that enables a predetermined chemical reaction or biological analysis, which is manufactured using so-called microfabrication technology. As disclosed in Patent Document 1, the inlet and outlet of a solution in the microchannel are disposed at a position higher in the direction of gravity than the outlet, so that the solution can be flowed through the microchannel without using an external source such as a pump or aspirator.

[0007] Furthermore, Patent Document 2 discloses an apparatus in which a plurality of test chambers are arranged parallel to the direction of gravity for performing tests such as immunoassays, PCR, and DNA hybridization. In the apparatus disclosed in Patent Document 2, a single opening is formed at a predetermined height position in the test chamber so that liquid is filled in the test chamber from the bottom by gravity, and liquid is supplied from the opening. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] WO2010 / 061598 [Patent Document 2] Special table 2015-516085 Summary of the Invention [Problem to be solved by the invention]

[0009] However, no system has been disclosed that utilizes a microchannel device to carry out the steps of extracting nucleic acid from cells and recovering the nucleic acid using magnetic beads, and the technical issues in this step are not suggested at all by the above-mentioned Patent Documents 1 and 2, or by the well-known techniques. When a system was actually constructed that utilizes a microchannel device to carry out the steps of extracting nucleic acid from cells and recovering the nucleic acid using magnetic beads, the problem arose that it was difficult to obtain a highly pure nucleic acid solution.

[0010] Therefore, an object of the present invention is to provide a nucleic acid extraction device capable of obtaining a high-purity nucleic acid solution when recovering nucleic acids extracted from cells or the like using magnetic beads, a nucleic acid analysis device equipped with the nucleic acid extraction device, and a nucleic acid extraction method. [Means for solving the problem]

[0011] In order to achieve the above-mentioned object, the inventors conducted extensive research and discovered that by controlling the shape of the microchannel into which the magnetic beads are placed and the position of the magnetic beads when passing through the microchannel, a highly pure nucleic acid solution can be obtained using the magnetic beads, thereby completing the present invention. The present invention encompasses the following:

[0012] (1) A chamber having an inlet and an outlet, the inlet being located higher in the direction of gravity than the outlet and tapering toward the outlet, and containing magnetic beads capable of adsorbing nucleic acids; a magnetic bead control unit having a magnetic body that applies a magnetic force to the inside of the chamber and a drive unit that moves the magnetic body between the inlet and the outlet of the chamber; The nucleic acid extraction apparatus, wherein the magnetic bead control unit is capable of positioning the magnetic bodies at the tapered position in the chamber. (2) The nucleic acid extraction apparatus described in (1) is characterized in that, when the chamber is filled with solution, the magnetic bead control unit moves the magnetic body between the inlet and outlet portions of the chamber using a drive unit, thereby stirring the solution filled in the chamber using the magnetic beads. (3) The nucleic acid extraction apparatus according to (1), characterized in that when liquid is passed through the chamber from the inlet portion to the outlet portion, the magnetic bead control unit positions the magnetic body at the tapered position in the chamber. (4) The nucleic acid extraction apparatus according to (1), further comprising an inlet flow channel and an outlet flow channel connected to the inlet and outlet portions of the chamber, respectively. (5) The nucleic acid extraction apparatus according to (4), further comprising: a plurality of tanks connected to the outlet flow path; and a switching valve disposed in the outlet flow path for switching between and connecting the chamber to any one of the plurality of tanks. (6) The nucleic acid extraction apparatus according to (4), further comprising: a first substrate on which the inlet flow path and a portion of the outlet flow path are formed; a second substrate and a third substrate which are combined with the first substrate to form the chamber; and a fourth substrate and a fifth substrate on which the remainder of the outlet flow path is formed and which are combined with the first substrate to form the entire outlet flow path. (7) The nucleic acid extraction device according to (4), further comprising a plurality of the inlet flow paths and a plurality of reagent injection ports connected to the plurality of inlet flow paths. (8) A nucleic acid analyzer for analyzing nucleic acid extracted from a sample, comprising: An extraction unit including the nucleic acid extraction device according to any one of (1) to (7) above; A nucleic acid analyzer comprising an analysis unit connected to the extraction unit via a flow path and configured to analyze nucleic acids contained in the solution recovered by the nucleic acid extraction device. (9) The nucleic acid analysis apparatus according to (8), wherein the analysis unit includes a nucleic acid amplification unit that performs a nucleic acid amplification reaction using the nucleic acid contained in the solution recovered by the nucleic acid extraction device as a template, a hybridization unit that performs hybridization between the nucleic acid amplified in the nucleic acid amplification unit and a nucleic acid probe, and a detection unit that detects hybridization between the nucleic acid probe and the nucleic acid in the hybridization unit. (10) The nucleic acid analyzer according to (9), wherein the hybridization section includes a DNA chip. (11) The nucleic acid analyzer according to (9), wherein the nucleic acid probe includes a nucleic acid probe for detecting a target nucleic acid having a sequence complementary to a region including a target base to be detected in a gene mutation in a target nucleic acid amplified in the nucleic acid amplification unit, and a nucleic acid probe for detecting a non-target nucleic acid having a sequence complementary to a region including a non-target base to be detected in a non-target nucleic acid including a non-target base corresponding to the target base to be detected. (12) The nucleic acid analyzer according to (9), wherein the analysis unit quantitatively analyzes a target nucleic acid containing a base to be detected in a gene mutation. (13) a step of supplying an elution solution for eluting the nucleic acid from the magnetic beads into a chamber having an inlet and an outlet, the inlet being located higher in the direction of gravity than the outlet and tapering toward the outlet, in a state in which magnetic beads having nucleic acid adsorbed thereon are retained in the chamber; applying a magnetic force from outside the chamber to magnetically collect the magnetic beads at the tapered position; and discharging an eluate containing nucleic acid from the outlet port while magnetic beads are collected at the tapered position. (14) The method for extracting nucleic acid according to (13), further comprising the steps of: supplying a solution containing a biological sample into the chamber from the inlet portion prior to the step of supplying the elution solution into the chamber; and then moving a magnetic body disposed outside the chamber between the inlet portion and the outlet portion to stir the solution with magnetic beads in the chamber, characterized in that nucleic acid derived from the biological sample is adsorbed onto the surface of the magnetic beads by this step. (15) The method for extracting nucleic acid according to (14), further comprising a step of discharging a solution from the outlet while the magnetic beads are magnetically collected at the tapered position after the nucleic acid derived from the biological sample is adsorbed onto the surface of the magnetic beads, and the solution discharged in this step and an eluate containing the nucleic acid are collected in different tanks. (16) The nucleic acid extraction method according to (14), wherein the outlet portion and the plurality of tanks are connected via an outlet flow path having a switching valve disposed therein, and the switching valve switches between and connects the chamber to any one of the plurality of tanks. Effect of the Invention

[0013] According to the nucleic acid extraction device and nucleic acid extraction method of the present invention, a highly pure nucleic acid solution can be obtained using magnetic beads. Therefore, by applying the nucleic acid extraction device or nucleic acid extraction method of the present invention, it is possible to perform highly accurate nucleic acid analysis using the highly pure nucleic acid solution.

[0014] According to the nucleic acid analyzer of the present invention, a highly pure nucleic acid solution can be obtained by using magnetic beads, and nucleic acid analysis using the highly pure nucleic acid solution can be performed with high accuracy. [Brief description of the drawings]

[0015] [Figure 1] 1 is a perspective view of a main part showing an example of a nucleic acid extraction apparatus to which the present invention is applied. [Diagram 2] FIG. 2 is an exploded perspective view of a main part of the nucleic acid extraction device shown in FIG. [Diagram 3] FIG. 13 is an exploded perspective view of a main part showing another example of a nucleic acid extraction apparatus to which the present invention is applied. [Figure 4] FIG. 4 is a front view of the nucleic acid extraction device shown in FIG. 3. [Diagram 5] FIG. 4 is a bottom view of the nucleic acid extraction device shown in FIG. 3. [Figure 6] FIG. 4 is a left side view of the nucleic acid extraction device shown in FIG. 3. [Figure 7] FIG. 4 is a right side view of the nucleic acid extraction device shown in FIG. 3. [Figure 8] 4 is a perspective view of the essential parts of the nucleic acid extraction apparatus shown in FIG. 3, illustrating the operation of filling a solution through a second reagent inlet and transferring the solution to a waste liquid recovery tank. FIG. [Figure 9] 4 is a perspective view of the essential parts of the nucleic acid extraction apparatus shown in FIG. 3, illustrating the operation of filling a solution through a first reagent inlet and transferring the solution to a DNA recovery tank. FIG. [Figure 10] 1 is a schematic diagram showing the configuration of a genetic mutation testing device equipped with a nucleic acid analyzer. [Figure 11] 1 is a flowchart showing the steps from PCR to fluorescent observation of a DNA chip in a genetic mutation testing device. [Figure 12] FIG. 2A is a top view and FIG. 2B is a longitudinal sectional view of the nucleic acid extraction device used in Comparative Examples 1 and 2 and Example 1. [Figure 13] FIG. 1A is a top view and FIG. 1B is a side view showing the nucleic acid extraction procedure of Comparative Example 2. [Figure 14] FIG. 1A is a top view and FIG. 1B is a side view showing the nucleic acid extraction procedure of Example 1. [Figure 15] FIG. 2 is a characteristic diagram showing the nucleic acid concentrations contained in the nucleic acid solutions recovered in Comparative Examples 1 and 2 and Examples 1 and 2. [Figure 16] FIG. 2 is a characteristic diagram showing the fluorescence intensity from the DNA chips measured in Comparative Examples 1 and 2 and Examples 1 and 2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A nucleic acid extraction device, a nucleic acid analysis device including the nucleic acid extraction device, and a nucleic acid extraction method according to the present invention will be described in detail with reference to the drawings.

[0017] [First embodiment] One embodiment of the nucleic acid extraction device according to the present invention is shown in FIG. 1. As shown in FIG. 1, the nucleic acid extraction device 1 includes a chamber 4 having an inlet 2 serving as an inlet for various solutions and an outlet 3 for discharging the internal solutions, magnetic beads 5 loaded in the chamber 4, and a magnetic bead control unit 6 for applying a magnetic force to the magnetic beads 5 loaded in the chamber 4. The inlet 2 of the chamber 4 is formed at a higher position in the direction of gravity than the outlet 3. In the example shown in FIG. 1, the longitudinal direction of the chamber 4 (the direction connecting the inlet 2 and the outlet 3) is parallel to the direction of gravity, the inlet 2 is formed on the upper side, and the outlet 3 is formed on the lower side. In addition, the chamber 4 has a tapered shape toward the outlet 3. In other words, the chamber 4 has a shape (which can also be called a funnel shape) in which the area of ​​the cross section (cross section perpendicular to the direction of gravity) becomes smaller toward the outlet 3.

[0018] 1, the longitudinal direction of the chamber 4 is parallel to the direction of gravity, but the longitudinal direction of the chamber 4 may be inclined with respect to the direction of gravity if the inlet 2 is located higher than the outlet 3. However, in the nucleic acid extraction apparatus, the longitudinal direction of the chamber 4 is preferably inclined at an angle of 10 degrees or less with respect to the direction of gravity, and most preferably the longitudinal direction of the chamber 4 is parallel to the direction of gravity.

[0019] The magnetic beads 5 may be appropriately used as those used in DNA extraction techniques or DNA purification techniques generally referred to as the magnetic bead method. For example, various commercially available magnetic beads may be used as the magnetic beads 5. The particle size of the magnetic beads 5 is not particularly limited as long as they can be introduced into the chamber 4 from the inlet 2 or the like, but is preferably about 0.1 μm to 20 μm, and more preferably about 0.5 μm to 10 μm.

[0020] The magnetic bead control unit 6 includes a magnetic body 7 that applies a magnetic force to the magnetic beads 5 loaded in the chamber 4, and a drive unit 8 that reciprocates the magnetic body 7 in the longitudinal direction of the chamber 4. In the example shown in Fig. 1, the drive unit 8 includes a belt 9 and a pair of pulleys 10A and 10B arranged along the longitudinal direction of the chamber 4 (belt-pulley mechanism), and a power source 12 is connected to one of the pulleys, 10A, via a drive shaft 11.

[0021] Here, in the nucleic acid extraction device 1, the magnetic beads 5 can be collected by the magnetic bead control unit 6 at the tapered portion 13 formed near the outlet 3 of the chamber 4. The magnetic body 7 in the magnetic bead control unit 6 applies a magnetic force to the tapered portion 13, so that the magnetic beads 5 can be collected at the tapered portion 13. More specifically, the magnetic bead control unit 6 can cause the magnetic body 7 to reciprocate between the pair of pulleys 10A and 10B by the above-mentioned belt-pulley mechanism (the range indicated by "H" in FIG. 1), and can stop the magnetic body 7 at a position facing the tapered portion 13. This allows the magnetic beads 5 to be collected at the tapered portion 13. In the example shown in FIG. 1, the pulley 10B is disposed at the position of the outlet 3 or below the outlet 3, and the power source 12 is controlled by a control device (not shown) to stop the magnetic body 7 at a position facing the tapered portion 13, so that the magnetic beads 5 can be collected at the tapered portion 13.

[0022] The chamber 4 in the nucleic acid extraction apparatus 1 shown in Fig. 1 can be produced by bonding multiple substrates together, as shown in Fig. 2. In the example shown in Fig. 2, the chamber 4 can be formed by stacking a first substrate 14, a second substrate 15, and a third substrate 16 in this order and bonding them together.

[0023] In addition, the first substrate 14 is formed with the inlet portion 2, the outlet portion 3, and grooves 17A and 17B communicating with the inlet portion 2 and the outlet portion 3, respectively, and a recess 18 constituting the chamber 4 is formed between the grooves 17A and 17B. The second substrate 15 is formed with an opening 19 having the same shape as the grooves 17A and 18B and the recess 18 formed in the first substrate 14. The third substrate 16 is a flat plate member. By bonding the first substrate 14, the second substrate 15, and the third substrate 16 together, the chamber 4 is formed by the grooves 17A and 17B and the recess 18 formed in the first substrate 14, the opening 19 formed in the second substrate 15, and the third substrate 16.

[0024] The first substrate 14, the second substrate 15, and the third substrate 16 are not particularly limited, and may be made of, for example, polyethylene terephthalate (PET), polycarbonate (PC), polymethyl methacrylate (PMMA), polyvinyl chloride (PVC), polypropylene (PP), polyethylene (PE), polystyrene (PS), ABS resin, cycloolefin polymer (COP), cycloolefin copolymer (COC), polydimethylsiloxane (PDMS), polyimide, polyether, silicone resin, elastomer, or other polymeric material or glass. The first substrate 14, the second substrate 15, and the third substrate 16 may all be made of the same material, or may be made of different materials. The second substrate 15 may also be made of a material coated with an adhesive on both sides in order to bond the first substrate 14 and the third substrate 16 to both main surfaces.

[0025] The method for forming the grooves 17A and 17B in the first substrate 14 and the method for forming the openings 19 in the second substrate 15 are not particularly limited, but examples of the method include cutting, injection molding, hot embossing, laser processing, and etching. The method for bonding the first substrate 14, the second substrate 15, and the third substrate 16 is not particularly limited, but examples of the method include heat fusion, laser welding, ultrasonic welding, adhesion using a solvent, adhesive, pressure sensitive adhesive, and the like, and a method of activating the surface by plasma treatment or ultraviolet treatment and then bonding them under pressure.

[0026] In the above-described example, the chamber 4 is formed by bonding the first substrate 14, the second substrate 15, and the third substrate 16 together, but the chamber 4 may also be formed by bonding the first substrate 14 and the third substrate 16 together.

[0027] 1, the nucleic acid extraction apparatus 1 is provided with a microchannel connected to the inlet 2, and one or more reagent inlets connected to the chamber 4 via the microchannel and the inlet 2. The reagent inlets can be connected to a syringe pump filled with a cell suspension, a cell lysis solution, a washing solution, ethanol, magnetic beads 5, an elution solution, or the like. When the nucleic acid extraction apparatus 1 has multiple reagent inlets, it is provided with a microchannel for each reagent inlet, and a connection between the chamber 4 and the reagent inlet can be established by a switching valve or the like.

[0028] 1, the nucleic acid extraction apparatus 1 includes a microchannel connected to the outlet 3, and one or more tanks connected to the chamber 4 via the microchannel and the outlet 3. When multiple tanks are included, the nucleic acid extraction apparatus 1 includes a microchannel for each tank, and the connection between the chamber 4 and the tanks can be established by a switching valve or the like. Examples of the multiple tanks include a tank for recovering nucleic acids, a tank for recovering waste liquid, and the like.

[0029] The nucleic acid extraction device 1 configured as above can extract and purify nucleic acids (DNA and / or RNA) contained in a biological sample such as cells. Here, "extracting and purifying nucleic acids" means extracting nucleic acids by dissolving or homogenizing a biological sample, and separating them from contaminants other than nucleic acids (proteins, enzymes, lipid components, etc.). In particular, when the above-mentioned nucleic acid extraction device is applied, "extracting and purifying nucleic acids" means recovering a nucleic acid solution in which the nucleic acids adsorbed to the magnetic beads 5 are eluted into an elution solution. The recovered nucleic acid solution contains few contaminants such as proteins, making it a high-purity nucleic acid solution.

[0030] A method for extracting and purifying nucleic acids from cells using the nucleic acid extraction device 1 will be described below by way of example. First, a cell suspension containing cells to be treated and a dissolution solution, and magnetic beads 5 are injected into the chamber 4. In this state, the magnetic body 7 in the magnetic bead control unit 6 is reciprocated in the range H in FIG. 1. This allows the solution filled with the magnetic beads 5 in the chamber 4 to be stirred, and the cells contained in the solution can be crushed and the nucleic acids can be adsorbed to the magnetic beads 5. The magnetic body 7 is not limited to a form in which it reciprocates in the entire range H in FIG. 1, but may be a form in which it reciprocates in a part of the range H. The magnetic body 7 is not limited to a form in which it reciprocates in the entire range or a part of the range H in FIG. 1, but may perform a rotational motion or a right-left reciprocating motion within the range H. In other words, the rotational motion or reciprocating motion within the range H by the magnetic body 7 can efficiently perform stirring.

[0031] Next, the magnetic body 7 in the magnetic bead control unit 6 is positioned near the outlet 3 to magnetically collect the magnetic beads 5 at the tapered portion 13. In this state, the solution in the chamber 4 is collected from the outlet to a waste liquid tank (not shown). In the nucleic acid extraction device 1, the inlet 2 is formed at a higher position in the direction of gravity than the outlet 3, so that the liquid in the chamber 4 can be transferred from the outlet 3 to the tank by connecting the inlet 2 to the outside and setting the inside of the chamber 4 to the outside air pressure. Note that a discharge pump may be attached to the inlet 2 via a microchannel, or a suction pump may be attached to the outlet 3 via a microchannel, and the liquid in the chamber 4 may be transferred from the outlet 3 to the tank using the discharge pump and / or the suction pump.

[0032] Next, a washing solution is poured into the chamber 4. In this state, the magnetic body 7 in the magnetic bead control unit 6 is caused to reciprocate within the range H in Fig. 1. This allows the magnetic beads 5 to agitate the washing solution filled in the chamber 4, and the magnetic beads 5 and the chamber 4 can be washed with the washing solution while maintaining the state in which the nucleic acid is adsorbed.

[0033] Next, the magnetic body 7 in the magnetic bead control unit 6 is positioned near the outlet 3 to magnetically collect the magnetic beads 5 at the tapered portion 13. In this state, the cleaning liquid in the chamber 4 is collected from the outlet to a waste liquid tank (not shown) in the same manner as above. This makes it possible to remove impurities (proteins, lipids, etc.) remaining on the surfaces of the magnetic beads 5 and the inner walls of the chamber 4. Note that in this case as well, the cleaning liquid in the chamber 4 may be transferred from the outlet 3 to the tank using a discharge pump and / or a suction pump. The cleaning process using the cleaning liquid may be carried out multiple times.

[0034] Next, ethanol is injected into the chamber 4. In this state, the magnetic body 7 in the magnetic bead control unit 6 is caused to reciprocate within the range H in Fig. 1. This allows the magnetic beads 5 to stir the ethanol filling the chamber 4, and the magnetic beads 5 and chamber 4 can be washed with ethanol while maintaining the state in which the nucleic acid is adsorbed.

[0035] Next, the magnetic body 7 in the magnetic bead control unit 6 is positioned near the outlet 3 to magnetically collect the magnetic beads 5 at the tapered portion 13. In this state, the ethanol in the chamber 4 is collected from the outlet into a waste liquid tank (not shown) in the same manner as above. This makes it possible to remove the washing liquid remaining on the surfaces of the magnetic beads 5 and the inner walls of the chamber 4. Note that in this case as well, the ethanol in the chamber 4 may be transferred from the outlet 3 to the tank using a discharge pump and / or a suction pump.

[0036] Next, in order to elute the nucleic acid adsorbed to the magnetic beads 5, an elution liquid (e.g., distilled water or purified water) is injected into the chamber 4. In this state, the magnetic body 7 in the magnetic beads control unit 6 is caused to reciprocate within the range H in FIG. 1. This allows the magnetic beads 5 to agitate the elution liquid filled in the chamber 4, and the nucleic acid is eluted from the magnetic beads 5.

[0037] Next, the magnetic body 7 in the magnetic bead control unit 6 is positioned near the outlet 3 to magnetically collect the magnetic beads 5 at the tapered portion 13. In this state, the solution containing nucleic acid (nucleic acid solution) in the chamber 4 is recovered from the outlet to a tank for recovering nucleic acid (not shown) in the same manner as described above. This allows nucleic acid derived from the cells to be treated to be recovered in the tank. In this case, the nucleic acid solution in the chamber 4 may also be transferred from the outlet 3 to the tank using a discharge pump and / or a suction pump.

[0038] As described above, nucleic acids can be extracted and purified from cells to be treated by the nucleic acid extraction apparatus 1. In the nucleic acid extraction apparatus 1, the inlet section 2 is formed at a higher position in the direction of gravity than the outlet section 3, and has a tapered section 13, so that liquids in the chamber 4 (solution after cell disruption, washing liquid, ethanol, etc.) can be reliably discharged from the outlet section 3 by gravity. In other words, it is possible to prevent liquids from remaining in the chamber 4.

[0039] According to the nucleic acid extraction device 1, it is possible to prevent contamination with ethanol or a washing solution when recovering a nucleic acid solution, and therefore it is possible to obtain a nucleic acid solution of high purity. In particular, since it is possible to prevent contamination with ethanol, which is an inhibitor in a nucleic acid amplification reaction, the nucleic acid solution obtained using the nucleic acid extraction device 1 can be used in a nucleic acid amplification reaction without undergoing a process to remove ethanol.

[0040] Furthermore, in the nucleic acid extraction apparatus 1, the liquid in the chamber 4 (such as the solution after cell disruption, washing solution, ethanol, and nucleic acid solution) is discharged from the chamber 4 while the magnetic beads 5 are magnetically collected at the tapered portion 13. Therefore, when discharging the solution from the outlet portion 3, the magnetic beads 5 can be maintained in contact with the solution, the magnetic beads 5 can be reliably washed with the washing solution or ethanol, and the nucleic acids adsorbed to the magnetic beads 5 can be reliably eluted with the elution solution. Therefore, the nucleic acid extraction apparatus 1 can efficiently extract nucleic acids from the cells to be treated.

[0041] In contrast, in the nucleic acid extraction device 1, if the liquid in the chamber 4 is discharged in a state in which the magnetic beads 5 are magnetically collected upward in the direction of gravity from the tapered portion 13, the magnetic beads 5 will not be immersed in the liquid when the liquid is discharged from the outlet portion 3. In this case, therefore, the washing effect of the washing solution or ethanol will decrease, and the amount of nucleic acid eluted in the elution solution will decrease.

[0042] Furthermore, the nucleic acid extraction apparatus 1 can agitate the liquid in the chamber 4 (such as the solution after cell disruption, washing liquid, ethanol, and nucleic acid solution) by the magnetic body 7 reciprocating within the range H in FIG. 1. In other words, the nucleic acid extraction apparatus 1 does not require components such as a centrifuge or vibration generator for agitating the liquid in the chamber 4. A centrifuge or vibration generator can reduce the robustness of the entire apparatus and can reduce the relative positional accuracy with respect to external control components. Therefore, the nucleic acid extraction apparatus 1 can avoid these inconveniences.

[0043] Furthermore, as described above, the nucleic acid extraction apparatus 1 can extract nucleic acids from samples with a very simple configuration. Therefore, even if a new nucleic acid extraction apparatus 1 is used for each sample, it is possible to process many samples at low cost. Alternatively, the nucleic acid extraction apparatus 1 can be used repeatedly for multiple samples by cleaning the inside of the chamber 4.

[0044] Second Embodiment Another embodiment of the nucleic acid extraction device according to the present invention is shown in FIG. 3. As shown in FIG. 3, the nucleic acid extraction device 20 is a device formed by combining a plurality of substrates on which microchannels are formed by cutting or the like. In the following description of the nucleic acid extraction device 20 according to the second embodiment, the same components as those in the nucleic acid extraction device 1 according to the first embodiment are given the same reference numerals, and detailed description thereof will be omitted. In addition, a front view of the nucleic acid extraction device 20 as viewed from the surface on which the chamber 4 is formed is shown in FIG. 4, a bottom view is shown in FIG. 5, a left side view of the front view of FIG. 4 with the gravity direction downward is shown in FIG. 6, and a right side view of the front view of FIG. 4 is shown in FIG. 7.

[0045] In the nucleic acid extraction apparatus 20, the longitudinal direction of a chamber 4 having a pair of inlet portions 2A and 2B, an outlet portion 3, and a tapered portion 13 is parallel to the direction of gravity, and the inlet portions 2A and 2B are positioned higher than the outlet portion 3. In the nucleic acid extraction apparatus 20, an air intake 21 is formed in the upper portion of the chamber 4. In the nucleic acid extraction apparatus 20, the chamber 4 is formed by combining a second substrate 23 and a third substrate 24 with one main surface 22A of a housing 22 (corresponding to the first substrate 14 in the first embodiment).

[0046] The second substrate 23 has an opening 26 formed therein, the opening 26 having the same shape as the recess 25 formed in the one main surface 22A. The third substrate 24 is a flat plate member. By combining the one main surface 22A, the second substrate 23, and the third substrate 24, the recess 25 formed in the one main surface 22A, the opening 26 formed in the second substrate 23, and the third substrate 24, the chamber 4 is formed.

[0047] The nucleic acid extraction apparatus 20 is not limited to a configuration in which the chamber 4 is formed by combining the second substrate 23 and the third substrate 24 on one main surface 22A of the housing 22 as described above, but may be configured to form the chamber 4 by combining a substrate having a recess 25 (corresponding to the first substrate 14 in the first embodiment) with the second substrate 23 and the third substrate 24, and attaching this to the housing 22.

[0048] The housing 22 has a first reagent inlet 27 and a second reagent inlet 28 on the upper surface, a first inlet flow path 29 that communicates the first reagent inlet 27 with the inlet section 2A, and a second inlet flow path 30 that communicates the second reagent inlet 28 with the inlet section 2B. The housing 22 also has a DNA recovery tank 31 and a waste liquid recovery tank 32 inside, a first outlet flow path 33 that communicates the DNA recovery tank 31 with the outlet section 3, and a second outlet flow path 34 that communicates the waste liquid recovery tank 32 with the outlet section 3. The first outlet flow path 33 and the second outlet flow path 34 join together midway and are connected to the outlet section 3 as a single flow path. In addition, recesses that become the first outlet flow path 33 and the second outlet flow path 24 are formed on the lower surface of the housing 22.

[0049] In the nucleic acid extraction device 20, the first outlet flow path 33 and the second outlet flow path 34 are formed by combining a fourth substrate 36, in which openings 35 serving as the first outlet flow path 33 and the second outlet flow path 34 are formed, and a fifth substrate 37, which is a flat plate member, on the lower surface of the housing 22. That is, parts of the first outlet flow path 33 and the second outlet flow path 34 are formed in the housing 22, and the remaining parts of the first outlet flow path 33 and the second outlet flow path 34 are formed on the lower surface of the housing 22 and the fourth substrate 36.

[0050] Although not shown in detail, the first inlet flow path 29, the second inlet flow path 30, the first outlet flow path 33, and the second outlet flow path 34, which are connected inside the housing 22, can be formed by stacking a plurality of substrates having grooves formed therein, similar to the chamber 4. By stacking these substrates, the first reagent injection port 27 and the second reagent injection port 28, which have different opening directions, can be connected to the inlets 2A and 2B, and the DNA recovery tank 31 and the waste liquid recovery tank 32 can be connected to the outlet 3. The first inlet flow path 29, the second inlet flow path 30, the first outlet flow path 33, and the second outlet flow path 34 may be formed of piping or soft tubes.

[0051] A plurality of valves 38A, 38B, and 38C are provided in the first outlet flow path 33 and the second outlet flow path 34. By appropriately opening and closing the plurality of valves 38A, 38B, and 38C, it is possible to control the communication between the first outlet flow path 33 or the second outlet flow path 34 and the outlet section 3. Although not shown for simplification, the plurality of valves 38A, 38B, and 38C are provided with actuators on the outside of the housing 22, and the actuators drive the valves 38A, 38B, and 38C from the outside in response to control signals from the control device, thereby controlling the opening and closing of the first outlet flow path 33 and the second outlet flow path 34. In addition, valves 39A and 39B are provided on the first inlet flow path 29 and the second inlet flow path 30, respectively. These valves 39A and 39B are also provided with actuators, and the actuators drive the valves 39A and 39B from the outside in response to control signals from the control device, thereby controlling the opening and closing of the first inlet flow path 29 and the second inlet flow path 30.

[0052] As shown in Fig. 6, in order to operate the first inlet flow path 29 and the second inlet flow path 30 from the outside with an actuator (not shown), the first inlet flow path 29 and the second inlet flow path 30 first follow a path along the left side surface of the housing 22, and the valves 39A and 39B are also formed within the left side surface. Fig. 6 is drawn with the substrate (not shown) which is the outer left surface of the housing 22 removed, so that the surface on which the recesses which become the first inlet flow path 29 and the second inlet flow path 30 are formed can be seen.

[0053] In the nucleic acid extraction apparatus 20, the housing 22, the second substrate 23, the third substrate 24, the fourth substrate 36, the fifth substrate 37, and the outer substrate (not shown) can be made of the same materials as those in the first embodiment. However, the fifth substrate 37 that receives the operation of an actuator (not shown) and the substrate (not shown) on the left outer surface of the housing 22 are preferably made of a flexible material.

[0054] 3 to 7 show only the magnetic body 7 and do not show the configuration of the magnetic bead control unit 6, the nucleic acid extraction device 20 also includes a magnetic bead control unit 6 that applies a magnetic force to the magnetic beads 5 loaded in the chamber 4, and can reciprocate the magnetic body 7 in the direction of gravity by a mechanism such as an actuator. Also in the nucleic acid extraction device 20, the magnetic body 7 can be reciprocated in the direction of gravity and positioned in the vicinity of the outlet 3.

[0055] The nucleic acid extraction apparatus 20 configured as above can extract and purify nucleic acids (DNA and / or RNA) contained in a biological sample such as cells, similarly to the above-mentioned nucleic acid extraction apparatus 1. A method for extracting and purifying nucleic acids from cells using the nucleic acid extraction apparatus 20 will be described below as an example.

[0056] First, a cell suspension containing cells to be treated and a lysis solution and magnetic beads 5 are injected into the chamber 4 from the second reagent injection port 28 via the second inlet flow path 30 and the inlet section 2B, as shown in Fig. 8. The cell suspension and magnetic beads 5 may be injected from the second reagent injection port 28 using different syringe devices 40, or may be prepared in advance as a mixed solution and injected from the second reagent injection port 28 using the same syringe device 40.

[0057] Although not shown, with the cell suspension and the magnetic beads 5 filled in the chamber 4, the magnetic body 7 in the magnetic beads control unit 6 is reciprocated in the direction of gravity. This makes it possible to stir the solution in which the magnetic beads 5 are filled in the chamber 4, and to disrupt the cells contained in the solution and adsorb the nucleic acids to the magnetic beads 5.

[0058] Next, although not shown, the magnetic body 7 is positioned near the outlet 3 to magnetize the magnetic beads 5 to the tapered portion 13. In this state, the valves 38A and 38C are opened and the valve 38B is closed, thereby communicating the waste liquid recovery tank 32 with the outlet 3 through the second outlet flow path 34. In the nucleic acid extraction device 20, the inlets 2A and 2B are formed at a position higher in the direction of gravity than the outlet 3, and the chamber 4 can be made to have an outside air pressure by communicating with the outside through the intake port 21. Therefore, as shown in FIG. 8, the liquid in the chamber 4 can be transferred from the outlet 3 to the waste liquid recovery tank 32 through the second outlet flow path 34. In the nucleic acid extraction device 20, the liquid in the chamber 4 may also be transferred from the outlet 3 to the waste liquid recovery tank 32 through the second outlet flow path 34 using a discharge pump and / or a suction pump.

[0059] Next, similarly to the above-mentioned cell suspension and magnetic beads 5 (as shown in FIG. 8), a syringe device 40 filled with a washing solution is used to inject the washing solution from the second reagent inlet 28 through the second inlet flow path 30 and the inlet section 2B into the chamber 4. In this state, the magnetic body 7 in the magnetic bead control section 6 is caused to reciprocate in the direction of gravity. This allows the magnetic beads 5 to agitate the washing solution filled in the chamber 4, and the magnetic beads 5 and the chamber 4 to be washed with the washing solution while maintaining the state in which the nucleic acids are adsorbed.

[0060] Next, although not shown, the magnetic body 7 in the magnetic bead control unit 6 is positioned near the outlet 3 to magnetically collect the magnetic beads 5 at the tapered portion 13. In this state, the cleaning liquid in the chamber 4 can be transferred from the outlet 3 to the waste liquid recovery tank 32 via the second outlet flow path 34 in the same manner as described above. This makes it possible to remove impurities (proteins, lipids, etc.) remaining on the surfaces of the magnetic beads 5 and the inner walls of the chamber 4. In this case, the cleaning liquid in the chamber 4 may also be transferred from the outlet 3 to the waste liquid recovery tank 32 using a discharge pump and / or a suction pump. The cleaning process using the cleaning liquid may also be performed multiple times.

[0061] Next, in the same manner as the above-mentioned cell suspension, magnetic beads 5, and washing solution (as shown in FIG. 8), a syringe device 40 filled with ethanol is used to inject ethanol from the second reagent inlet 28 through the second inlet flow path 30 and the inlet section 2B into the chamber 4. In this state, the magnetic body 7 in the magnetic beads control section 6 is caused to reciprocate in the direction of gravity. This allows the magnetic beads 5 to agitate the ethanol filled in the chamber 4, and the magnetic beads 5 and chamber 4 can be washed with ethanol while maintaining the state in which the nucleic acids are adsorbed.

[0062] Next, although not shown, the magnetic body 7 in the magnetic bead control unit 6 is positioned near the outlet unit 3 to magnetically collect the magnetic beads 5 at the tapered portion 13. In this state, the ethanol in the chamber 4 can be transferred from the outlet unit 3 to the waste liquid recovery tank 32 via the second outlet flow path 34 in the same manner as described above. This makes it possible to remove the washing liquid remaining on the surfaces of the magnetic beads 5 and the inner walls of the chamber 4. Note that, in this case as well, the ethanol in the chamber 4 may be transferred from the outlet unit 3 to the waste liquid recovery tank 32 using a discharge pump and / or a suction pump.

[0063] Next, as shown in FIG. 9, in order to elute the nucleic acid adsorbed to the magnetic beads 5, an elution liquid (e.g., distilled water or purified water) is injected into the chamber 4 from the first reagent injection port 27 through the first inlet flow path 29 and the inlet section 2A. The syringe device 40 used to inject the elution liquid is different from the syringe device 40 used to inject the above-mentioned cell suspension and magnetic beads 5, washing liquid and ethanol, and is preferably disposable. Although not shown, in this state, the magnetic body 7 in the magnetic beads control section 6 is reciprocated in the direction of gravity. This allows the magnetic beads 5 to stir the elution liquid filled in the chamber 4, and the nucleic acid is eluted from the magnetic beads 5.

[0064] Next, although not shown, the magnetic body 7 in the magnetic bead control unit 6 is positioned near the outlet 3 to magnetize the magnetic beads 5 to the tapered portion 13. In this state, the valves 38A and 38B are opened and the valve 38C is closed, thereby communicating the DNA recovery tank 31 with the outlet 3 through the first outlet flow path 33. In the nucleic acid extraction device 20, the inlets 2A and 2B are formed at a position higher in the direction of gravity than the outlet 3, and the chamber 4 can be made to have an outside air pressure by communicating with the outside through the intake port 21. Therefore, as shown in FIG. 9, the liquid in the chamber 4 can be transferred from the outlet 3 to the DNA recovery tank 31 through the first outlet flow path 33. In the nucleic acid extraction device 20, the liquid in the chamber 4 may also be transferred from the outlet 3 to the DNA recovery tank 31 through the first outlet flow path 33 using a discharge pump and / or a suction pump.

[0065] As described above, nucleic acids can be extracted and purified from cells to be treated by the nucleic acid extraction apparatus 20. In the nucleic acid extraction apparatus 20, the inlets 2A and 2B are formed at a higher position in the direction of gravity than the outlet 3, and the chamber 4 has an air intake 21 at the top and a tapered portion 13, so that liquids in the chamber 4 (such as the solution after cell disruption, washing liquid, ethanol, etc.) can be reliably discharged from the outlet 3 by gravity. In other words, it is possible to prevent liquids from remaining in the chamber 4.

[0066] The nucleic acid extraction device 20 can prevent contamination with ethanol or washing liquid when recovering a nucleic acid solution, thereby obtaining a highly pure nucleic acid solution. In particular, since contamination with ethanol, which is an inhibitor in a nucleic acid amplification reaction, can be prevented, the nucleic acid solution obtained using the nucleic acid extraction device 20 can be used in a nucleic acid amplification reaction without undergoing a process to remove ethanol.

[0067] Furthermore, in the nucleic acid extraction device 20, the liquid in the chamber 4 (such as the solution after cell disruption, washing solution, ethanol, and nucleic acid solution) is discharged from the chamber 4 while the magnetic beads 5 are magnetically collected at the tapered portion 13. Therefore, when discharging the solution from the outlet portion 3, the magnetic beads 5 can be maintained in contact with the solution, the magnetic beads 5 can be reliably washed with the washing solution or ethanol, and the nucleic acid adsorbed to the magnetic beads 5 can be reliably eluted with the elution solution. Therefore, the nucleic acid extraction device 20 can efficiently extract nucleic acid from the cells to be treated.

[0068] In contrast, in the nucleic acid extraction device 20, if the liquid in the chamber 4 is discharged in a state in which the magnetic beads 5 are magnetically collected upward in the direction of gravity from the tapered portion 13, the magnetic beads 5 will not be immersed in the liquid when the liquid is discharged from the outlet portion 3. In this case, therefore, the washing effect of the washing solution or ethanol will decrease, and the amount of nucleic acid eluted in the elution solution will decrease.

[0069] Furthermore, the nucleic acid extraction apparatus 20 can agitate the liquid (solution after cell disruption, washing liquid, ethanol, nucleic acid solution, etc.) in the chamber 4 by the reciprocating motion of the magnetic body 7 in the direction of gravity. In other words, the nucleic acid extraction apparatus 20 does not require components such as a centrifuge or vibration generator for agitating the liquid in the chamber 4. A centrifuge or vibration generator can reduce the robustness of the entire apparatus and can reduce the relative positional accuracy with respect to external control parts. Therefore, the nucleic acid extraction apparatus 20 can avoid these inconveniences.

[0070] Furthermore, with the nucleic acid extraction apparatus 20 configured as described above, the operation of injecting a specimen or a reagent from the first reagent inlet 27 or the second reagent inlet 28, the operation of reciprocating motion of the magnetic body 7 using an actuator (not shown), the operation of the valves 38A, 38B and 38C using an actuator (not shown), and the access to the waste liquid recovery tank 32 can each be performed from different sides of the nucleic acid extraction apparatus 20. In this way, the nucleic acid extraction apparatus 20 has excellent operability.

[0071] Furthermore, the nucleic acid extraction apparatus 20 can extract nucleic acids from samples with a very simple configuration as described above. Therefore, even if a new nucleic acid extraction apparatus 20 is used for each sample, many samples can be processed at low cost. In this case, a new nucleic acid extraction apparatus 20 may be used for each sample, or only the chamber 4 and the DNA recovery tank 31 may be replaced for each sample. Alternatively, the nucleic acid extraction apparatus 20 can be used repeatedly for multiple samples by cleaning the inside of the chamber 4 and the DNA recovery tank 31.

[0072] Third embodiment A nucleic acid analyzer including the nucleic acid extraction devices 1 and 20 (hereinafter simply referred to as nucleic acid extraction devices) described in the third embodiment, the first embodiment, and the second embodiment will be described. The nucleic acid analysis device according to the present invention is not limited in any way as long as it is an analyzer that analyzes nucleic acids recovered by the nucleic acid extraction device. In this embodiment, an apparatus is described that performs a nucleic acid amplification reaction using the nucleic acid recovered by the nucleic acid extraction device as a template, and tests for genetic mutations based on hybridization between the obtained amplified fragment and a nucleic acid probe. That is, as shown in FIG. 10, a genetic mutation test device 50 includes an extraction unit 51 including a nucleic acid extraction device, and an analysis unit 53 that is connected to the extraction unit 51 via a flow path 52 and analyzes nucleic acids contained in a solution recovered by the nucleic acid extraction device.

[0073] Specifically, the analysis unit 53 includes a nucleic acid amplification reaction unit 54 that performs a nucleic acid amplification reaction to amplify a region containing a gene mutation to be tested, and a detection unit 55 that receives a reaction solution from the nucleic acid amplification reaction unit 54 and detects the target nucleic acid contained in the reaction solution. The nucleic acid amplification reaction unit 54 includes a reaction tank 56 that stores reagents and substances necessary for the nucleic acid amplification reaction, and a first temperature control unit 57 that controls the reaction solution in the reaction tank 56 to a predetermined temperature. The detection unit 55 includes a DNA chip mounting unit 59 that mounts a DNA chip 58 having a nucleic acid probe for detecting a target nucleic acid, a nucleic acid probe for detecting a non-target nucleic acid, a common probe, and the like (these various probes will be described later), a second temperature control unit 60 that controls the hybridization reaction solution supplied to the DNA chip 58 mounted on the DNA chip mounting unit 59 to a predetermined temperature, and an imaging unit 61 that is disposed at a position facing the surface of the DNA chip 58 to which the various probes are fixed. In the testing device 50, the nucleic acid amplification reaction unit 54 and the detection unit 55 are connected via a flow path 62 through which a solution can pass. The first temperature control section 57 and the second temperature control section 60 each include a metal block having high thermal conductivity and a temperature control device for heating / cooling the metal block.

[0074] The inspection device 50 also includes a hybridization buffer tank 64 connected to the DNA chip mounting section 59 via a flow path 63, and a cleaning liquid tank 66 connected to the DNA chip mounting section 59 via a flow path 65. The inspection device 50 also includes a waste liquid tank 68 connected to the DNA chip mounting section 59 via a flow path 67. The inspection device 1 also includes a pump device 70 connected to the waste liquid tank 68 via the flow path 69.

[0075] In the inspection device 50, liquid supply cutoff valves 71A, 71B, 71C, and 71D are provided in the flow paths 62, 63, 65, and 67. In the inspection device 50, intake valves 72A, 72B, 72C, and 72D are provided in the reaction chamber 56, the hybridization buffer tank 64, the washing liquid tank 66, and the waste liquid tank 68, respectively. The liquid supply cutoff valves 71A, 71B, 71C, and 71D can open and close the flow paths, and guide the pressure of the pump device 70 to the flow path to which the liquid is to be sent. That is, the inspection device 1 includes a liquid supply device including the pump device 70, the liquid supply cutoff valves 71A, 71B, 71C, and 71D, and the intake valves 72A, 72B, 72C, and 72D. This liquid delivery device can deliver various solutions to the testing section 55 via the flow paths 62 , 63 and 65 , and can deliver waste liquid to a waste liquid tank 68 via a flow path 67 .

[0076] In the testing device 50, the liquid delivery device can adjust the amount of reaction liquid delivered from the nucleic acid amplification reaction unit 54 to the testing unit 55 by timing control of the pump device 70, the liquid delivery shutoff valve 71A, and the intake valve 72A. However, the liquid delivery device in the testing device 50 may be provided with a measuring device on the flow path 62 that measures the reaction liquid delivered from the nucleic acid amplification reaction unit 54 to the testing unit 55. The liquid delivery device can measure a predetermined amount of reaction liquid using the measuring device and deliver the measured reaction liquid to the testing unit 55 via the flow path 62. The measuring device is not particularly limited, but examples thereof include a pipette and a space having a predetermined capacity.

[0077] Furthermore, when the reagent in the reaction chamber 56 or the DNA chip mounting portion 59 temporarily expands or contracts due to temperature fluctuation, these liquid supply cutoff valves 71A, 71B, 71C, and 71D can be moved to another portion connected by a flow path. The liquid supply cutoff valve is not particularly limited, and any valve that has been subjected to hydrophobic or hydrophilic treatment, or a material that changes shape due to heat or the like can be used without any limitation, but a shape that can be physically opened and closed by external stress is preferable, and as an example, it is preferable to use a diaphragm valve that is pressed by an actuator, or a rotary valve that is opened and closed by rotation.

[0078] In the testing device 50 configured as above, the target nucleic acid and the non-target nucleic acid contained in the nucleic acid amplification reaction solution are detected, and the target nucleic acid can be quantitatively analyzed based on the detection. A flow chart for quantitatively analyzing the target nucleic acid is shown in FIG. 11. To quantitatively analyze the target nucleic acid, first, a nucleic acid amplification reaction of a region containing a gene mutation to be tested is performed in the reaction vessel 56. At this time, the reaction vessel 56 is filled with a reaction solution consisting of reagents necessary for the nucleic acid amplification reaction. The reaction vessel 56 may be filled with the reaction solution by an operator, or the reaction vessel 56 may be filled with the reaction solution from a different flow path (not shown). In addition, by setting a thermal cycle in the nucleic acid amplification reaction in advance, the first temperature control unit 57 can control the temperature and processing time of the reaction solution in the reaction vessel 56 according to the set thermal cycle.

[0079] In the testing device 50, next, a part of the reaction liquid is sent to the DNA chip mounting portion 59 on which the DNA chip 58 is mounted. Specifically, the intake valve 72A and the liquid supply cutoff valves 71A and 71D are opened, and the other intake valves 72B, 72C, and 72D and the liquid supply cutoff valves 71B and 71C are closed. In this state, the pump device 70 is operated to send the reaction liquid in the reaction tank 56 to the DNA chip mounting portion 59.

[0080] At this time, the inspection device 50 can be set to temporarily halt the thermal cycle performed by the first temperature control unit 57 and wait until the liquid transfer is completed in one temperature range of the thermal cycle (for example, 95° C.).

[0081] Further, in addition to a part of the reaction solution, the hybridization buffer is supplied from the hybridization buffer tank 64 to the DNA chip mounting portion 59. To supply (send) the hybridization buffer to the DNA chip mounting portion 58, the pump device 70 is operated while the intake valve 72B and the liquid supply cutoff valves 71B and 71D are opened and the other intake valves 72A, 72C and 72D and the liquid supply cutoff valves 71A and 71C are closed. This allows the hybridization buffer in the hybridization buffer tank 64 to be sent to the DNA chip mounting portion 59. The hybridization buffer may have a composition containing a blocking nucleic acid, which will be described later.

[0082] As a result, hybridization of the target nucleic acid and non-target nucleic acid contained in the reaction solution with various probes of the DNA chip 58 proceeds in the DNA chip mounting section 59. At this time, the second temperature control section 60 adjusts the temperature of the solution supplied to the DNA chip mounting section 59 to a hybridization temperature set in advance. The second temperature control section 60 can also perform preheating before the reaction if necessary. In this example, the reaction solution and the hybridization buffer solution are separately sent through different flow paths, but the reaction solution and the hybridization buffer solution can also be mixed and then sent to the DNA chip mounting section 59 as a mixed solution.

[0083] Next, in the inspection device 50, the detection unit 55 detects the target nucleic acid and the non-target nucleic acid hybridized to the probe. Specifically, first, a cleaning liquid is sent to the DNA chip mounting unit 59 to clean the DNA chip 58. The cleaning liquid can be sent from the cleaning liquid tank 66. To supply (send) the cleaning liquid to the DNA chip mounting unit 59, the intake valve 72C and the liquid supply cutoff valves 71C and 71D are opened, and the other intake valves 72A, 72B, and 72D and the liquid supply cutoff valves 71A and 71B are closed, and the pump device 70 is operated. During this cleaning, the second temperature control unit 60 can also lower the cleaning temperature (for example, 25° C.) lower than the hybridization reaction temperature.

[0084] When washing the DNA chip 58, the mixture of the reaction solution and hybridization buffer solution may be discharged into the waste tank 68, and then the washing solution may be pumped as described above, or the mixture of the reaction solution and hybridization buffer solution may be discharged into the waste tank 68 by pumping the washing solution as described above.

[0085] The surface of the DNA chip 58 on which the nucleic acid probes for detecting target nucleic acids, the nucleic acid probes for detecting non-target nucleic acids, and the common probe are immobilized is imaged by a camera 61, and the signal intensity of each probe is measured by image analysis software in a computer (not shown). Based on the measured signal intensity, the target nucleic acid can be quantitatively analyzed by the same computer.

[0086] As described above, by using the inspection device 50 according to the present invention, it is possible to detect target nucleic acids and non-target nucleic acids based on the hybridization reaction with each probe using the DNA chip 58. In the above-mentioned example, the reaction vessel 56 and the DNA chip mounting portion 59 are connected via the flow path 62, and the nucleic acid amplification reaction liquid is delivered by a configuration including the pump device 70, the liquid delivery cutoff valves 71A, 71B, 71C, and 71D, and the intake valves 72A, 72B, 72C, and 72D. However, the mechanism for delivering the nucleic acid amplification reaction liquid (liquid delivery device) is not limited to such a configuration, and a part of the nucleic acid amplification reaction liquid can also be supplied by using a pipette device disposed on the drive arm.

[0087] 10, the above-mentioned liquid delivery operation is performed by suction using the pump device 70. However, the testing device 50 can also perform the above-mentioned liquid delivery operation by using a pressure pump connected upstream of the nucleic acid amplification reaction unit 54, the hybridization buffer tank 64, and the washing liquid tank 66.

[0088] In addition, in the testing device 50 shown in Figure 10, the hybridization buffer solution is sent directly to the DNA chip mounting section 59 from the hybridization buffer solution tank 64 connected to the DNA chip mounting section 59 via the flow path 63, but it may also be sent to the DNA chip mounting section 59 after first merging with the flow path 62.

[0089] 10 includes a DNA chip mounting section 59 on which a DNA chip 58 can be mounted, and the DNA chip 58 is detachably configured. However, the testing device 50 is not limited to such a configuration, and may have a configuration in which each probe is directly fixed to the detection section 55.

[0090] 10, the nucleic acid amplification reaction solution is delivered from a nucleic acid amplification reaction unit 54 having one reaction chamber 56, but the testing device to which the present invention is applied is not limited to this configuration. That is, the testing device to which the present invention is applied may be configured to include a nucleic acid amplification reaction unit 54 having a plurality of reaction chambers 56. In this case, the temperatures of the plurality of reaction chambers 56 may be collectively controlled by a single first temperature control unit 57, or the temperatures of the plurality of reaction chambers 56 may be individually controlled by the plurality of first temperature control units 57.

[0091] In this case, the inspection device 50 includes a liquid delivery device having flow paths connected to each of the multiple reaction chambers 56, and a switching device disposed on the flow paths and switching the flow paths that supply reaction liquid to the detection unit 55 between the multiple reaction chambers 56. That is, the liquid delivery device can connect one of the multiple reaction chambers 56 to the detection unit 55.

[0092] The following describes gene mutations to be tested in the above-mentioned testing device 50 and various probes to be mounted on the DNA chip.

[0093] The genetic mutation to be tested is, for example, a single nucleotide variant (SNV) or a single nucleotide polymorphism (SNP), which means a difference in a base at a specific position of genomic DNA. That is, for a specific genetic mutation, multiple bases are present. In the following description, one of these bases is referred to as a detection target base, and bases other than the detection target base are referred to as non-detection target bases.

[0094] The detection target base means, for example, a specific nucleic acid residue at a specific position of genomic DNA, and is not particularly limited, but means a specific type of base in a base sequence such as a single nucleotide polymorphism (SNP). For example, if a specific single nucleotide polymorphism can take A (adenine) or C (cytosine), either one of the bases, that is, A (adenine) in the single nucleotide polymorphism, can be the detection target base. Here, the detection target base may be either a major allele or a minor allele in a gene polymorphism, and may or may not be a risk allele.

[0095] Here, the target nucleic acid means a nucleic acid molecule containing a base to be detected, that is, a nucleic acid fragment. The target nucleic acid may be a nucleic acid molecule made of DNA, a nucleic acid molecule made of RNA, a nucleic acid molecule containing DNA and RNA (DNA-RNA complex), or a fragmented one such as cell-free DNA. In addition, the nucleic acid includes adenine, cytosine, guanine, thymine, and uracil, as well as artificial nucleic acids such as peptide nucleic acid (PNA) and locked nucleic acid (LNA).

[0096] The target nucleic acid containing the detection target base can be prepared by amplifying a specific region on genomic DNA containing a gene mutation by a nucleic acid amplification method. The target nucleic acid may also be cDNA obtained by reverse transcription reaction from a transcription product collected from an individual organism, tissue, or cell. The base length of the target nucleic acid is not particularly limited, but may be, for example, 60 to 1000 bases, preferably 60 to 500 bases, and more preferably 60 to 200 bases.

[0097] In addition, a nucleic acid molecule (nucleic acid fragment) containing a non-target base corresponding to a target base to be detected is called a non-target nucleic acid. For example, when one base among a plurality of bases that can be taken at a predetermined position in genomic DNA is taken as a target base to be detected, bases other than the target base to be detected are taken as non-target bases to be detected. More specifically, when a single nucleotide polymorphism at a predetermined position can take A (adenine) or C (cytosine), if A (adenine) in the single nucleotide polymorphism is taken as a target base to be detected, C (cytosine) in the single nucleotide polymorphism is taken as a non-target base to be detected.

[0098] Furthermore, for example, when a mutant type (forward or reverse strand of a minor allele) in a specific polymorphism or variant is used as a base to be detected, a nucleic acid fragment containing the mutant type can be used as a target nucleic acid, and a nucleic acid fragment containing a wild type (forward or reverse strand of a major allele), which is a base not to be detected, can be used as a non-target nucleic acid.

[0099] When the non-target base exists on genomic DNA for a specific gene mutation, the non-target nucleic acid containing the non-target base is obtained at the same time as the target nucleic acid containing the target base is obtained as described above.For example, when the target nucleic acid is obtained by a nucleic acid amplification reaction such as polymerase chain reaction, if one allele is a non-target base, the non-target nucleic acid is amplified together with the target nucleic acid.

[0100] In the above-mentioned genetic mutation testing device, in order to detect a target nucleic acid containing a target base, a nucleic acid probe having a base sequence complementary to at least a region containing the target base in the target nucleic acid is used. The nucleic acid probe is not particularly limited, but may be, for example, 10 to 30 bases long, and preferably 15 to 25 bases long. In addition, when the bases constituting the nucleic acid probe are viewed as a character string, the base complementary to the target base is preferably located at the center of the character string. Note that the center of the character string includes the case where the nucleic acid probe is shifted by one base toward the 5' end or 3' end in the case of a nucleic acid probe consisting of an even number of bases.

[0101] In particular, the above-mentioned genetic mutation testing device can use a common probe having a sequence complementary to a common region common to the target nucleic acid and the non-target nucleic acid. The common region is a region of a base sequence common to the target nucleic acid and the non-target nucleic acid, and does not contain a detection target base or a non-detection target base. For example, the common region can be a region that does not overlap with a region where a nucleic acid probe for detecting a target nucleic acid hybridizes and a region where a nucleic acid probe for detecting a non-target nucleic acid hybridizes.

[0102] The above-mentioned genetic mutation testing device can be applied to any system as long as it includes hybridization, which means complementary binding between nucleic acid molecules in a target nucleic acid and a nucleic acid probe. That is, the above-mentioned genetic mutation testing device can be based on Southern hybridization, Northern hybridization, or in situ hybridization. In particular, the above-mentioned genetic mutation testing device is preferably used in a system in which a nucleic acid probe is fixed to a carrier (including a substrate, hollow fiber, and microparticles) and the target nucleic acid is detected (including qualitative and quantitative) using the fixed nucleic acid probe. More specifically, the above-mentioned genetic mutation testing device uses a DNA chip (DNA microarray) in which a nucleic acid probe is fixed to a substrate.

[0103] Hereinafter, a system used for detecting a target nucleic acid using a DNA chip (DNA microarray) will be described. The above-mentioned nucleic acid probe for detecting a target nucleic acid (nucleic acid probe for detecting a target nucleic acid), the nucleic acid probe for detecting a non-target nucleic acid (nucleic acid probe for detecting a non-target nucleic acid), and the common probe are more preferably single-stranded DNA, and can be obtained by chemical synthesis using a nucleic acid synthesizer, for example. As the nucleic acid synthesizer, a device called a DNA synthesizer, a fully automatic nucleic acid synthesizer, an automatic nucleic acid synthesizer, etc. can be used.

[0104] In this example, the nucleic acid probe for detecting the target nucleic acid, the nucleic acid probe for detecting the non-target nucleic acid, and the common probe are preferably used in the form of a microarray by immobilizing their 5'-end or 3'-end on a carrier. The material of the carrier can be any known material in the art, and is not particularly limited. For example, conductive materials such as precious metals such as platinum, platinum black, gold, palladium, rhodium, silver, mercury, tungsten, and compounds thereof, and carbon such as graphite and carbon fiber; silicon materials such as single crystal silicon, amorphous silicon, silicon carbide, silicon oxide, silicon nitride, and composite materials of these silicon materials such as SOI (silicon-on-insulator); inorganic materials such as glass, quartz glass, alumina, sapphire, ceramics, forsterite, and photosensitive glass; polyethylene, polypropylene, cyclic Examples of the organic materials include polyolefin, polyisobutylene, polyethylene terephthalate, unsaturated polyester, fluorine-containing resin, polyvinyl chloride, polyvinylidene chloride, polyvinyl acetate, polyvinyl alcohol, polyvinyl acetal, acrylic resin, polyacrylonitrile, polystyrene, acetal resin, polycarbonate, polyamide, phenol resin, urea resin, epoxy resin, melamine resin, styrene-acrylonitrile copolymer, acrylonitrile-butadiene styrene copolymer, polyphenylene oxide, and polysulfone. The shape of the carrier is not particularly limited, but is preferably flat.

[0105] As the carrier, a carrier having a carbon layer such as diamond-like carbon (DLC) and a chemical modification group such as an amino group, a carboxyl group, an epoxy group, a formyl group, a hydroxyl group, and an active ester group on the surface is preferably used. The carrier having a carbon layer and a chemical modification group on the surface includes a substrate having a carbon layer and a chemical modification group on the surface, and a substrate made of a carbon layer having a chemical modification group on the surface. The substrate material can be any known material in the art, and is not particularly limited, and the same materials as those listed as the above-mentioned carrier materials can be used.

[0106] The above-mentioned genetic mutation testing device can quantitatively analyze the target nucleic acid in the subject using the DNA chip thus prepared. Specifically, the method includes the steps of: first, extracting DNA from a sample derived from the subject; and amplifying a region containing the genetic mutation of the test subject by a nucleic acid amplification reaction using the extracted DNA as a template, and detecting at least the target nucleic acid using the DNA chip in the exponential amplification phase of the nucleic acid amplification reaction.

[0107] The subject is usually a human being, and is a subject to be examined for genetic mutations, and may be a patient suffering from a disease associated with a specific genetic mutation. The sample derived from the subject is not particularly limited. For example, blood-related samples (blood, serum, plasma, etc.), lymph, feces, cancer cells, tissue or organ fragments and extracts, etc. may be included.

[0108] First, DNA is extracted from a sample collected from a subject. As an extraction means, the nucleic acid extraction device 1 or 20 described in the first and second embodiments described above is used. Next, an amplification reaction is performed using the obtained DNA as a template to amplify a nucleic acid region containing a gene mutation to be examined, preferably DNA. As the amplification reaction, a polymerase chain reaction (PCR), a loop-mediated isothermal amplification (LAMP), an isothermal and chimeric primer-initiated amplification of nucleic acids (ICAN) method, etc. can be applied. In the amplification reaction, it is desirable to add a label so that the region after amplification can be identified. At this time, the method of labeling the amplified nucleic acid is not particularly limited, but for example, a method of labeling the primer used in the amplification reaction in advance may be used, or a method of using a labeled nucleotide as a substrate in the amplification reaction may be used. As a labeling substance, it is not particularly limited, but a radioisotope, a fluorescent dye, or an organic compound such as digoxigenin (DIG) or biotin may be used.

[0109] This reaction system also contains a buffer necessary for nucleic acid amplification and labeling, a heat-stable DNA polymerase, a pair of primers specific to the region to be amplified, labeled nucleotide triphosphates (specifically, nucleotide triphosphates to which a fluorescent label or the like has been added), nucleotide triphosphates, and magnesium chloride.

[0110] Nucleic acid amplification reaction consists of three steps: denaturation, annealing, and extension. These three steps constitute one cycle, and by repeating multiple cycles, a nucleic acid fragment containing the genetic mutation to be tested can be synthesized. The procedure for repeating these three steps is called a thermal cycle, and the number of times the three steps are repeated is called the number of thermal cycles.

[0111] The nucleic acid amplification reaction may also be composed of two steps, a thermal denaturation step and an annealing and extension step, by performing annealing and extension at the same temperature, which is called 2-step PCR. In this case, by repeating these two steps as one cycle, a nucleic acid fragment containing the gene mutation to be tested can be synthesized. In this case, the procedure for repeating these two steps is called a thermal cycle, and the number of times the two steps are repeated is called the number of thermal cycles.

[0112] The thermal denaturation step is a step in which a reaction solution containing template DNA is heated to 90°C or higher to form single-stranded DNA. The first thermal denaturation step in the thermal cycle is preferably carried out for a relatively long time (1 to 5 minutes) when genomic DNA is used as a template. The second and subsequent thermal denaturation steps are preferably carried out for a relatively short time (1 to 90 seconds) since the purpose is to convert the amplified product obtained as a double strand into a single strand.

[0113] The annealing step is a step in which a reaction solution containing a single-stranded template DNA and a pair of primer sets is heated to a temperature usually in the range of 40 to 75°C, and these primers are specifically bound to the template DNA. The temperature of the annealing step is appropriately set depending on the sequence and length of the primers. The temperature of the annealing step is usually set within a range of ±5°C of the Tm value of the primer used.

[0114] The extension step is a step in which the temperature of the reaction solution is set to about 72° C. with the primer annealed to the template DNA, and a complementary strand is synthesized from the end of the primer by a heat-resistant polymerase (such as Taq DNA polymerase). In this reaction, the complementary strand of the template DNA is synthesized from a labeled primer, or the complementary strand of the template DNA is synthesized while incorporating a labeled free nucleotide. Thus, for the genetic mutation to be tested, the target nucleic acid containing the base to be detected and the non-target nucleic acid containing the base not to be detected are labeled. The time of the extension step is appropriately set depending on the length of the nucleic acid fragment to be amplified and the reactivity of the enzyme to be used.

[0115] In the above-mentioned genetic mutation testing device, the target nucleic acid and non-target nucleic acid contained in the nucleic acid amplification reaction solution are detected, and the target nucleic acid can be quantitatively analyzed based on the detection. To quantitatively analyze the target nucleic acid, a hybridization reaction between the target nucleic acid detection nucleic acid probe and the target nucleic acid is performed, and the amount of the nucleic acid hybridized to the target nucleic acid detection nucleic acid probe can be measured, for example, by detecting the label. For example, when a fluorescent label is used, the signal from the label can be detected as a fluorescent signal using a fluorescent scanner, and the signal intensity can be quantified by analyzing the signal using image analysis software.

[0116] The hybridization reaction is preferably carried out under stringent conditions. Stringent conditions refer to conditions under which specific hybrids are formed and non-specific hybrids are not formed, for example, conditions under which the hybridization reaction is carried out at 50°C for 16 hours, followed by washing at 2xSSC / 0.2% SDS at 25°C for 10 minutes and 2xSSC at 25°C for 5 minutes. That is, the hybridization buffer composition according to the present invention may contain salts necessary for the hybridization reaction, such as SSC, and known blocking agents, such as SDS.

[0117] Specifically, when a target nucleic acid is quantitatively analyzed based on signals from a nucleic acid probe for detecting a target nucleic acid and a nucleic acid probe for detecting a non-target nucleic acid, the signal intensities of the nucleic acid probe for detecting a target nucleic acid and the nucleic acid probe for detecting a non-target nucleic acid are measured, respectively, and a judgment value for evaluating the signal intensity from the nucleic acid probe for detecting a target nucleic acid is calculated. An example of the calculation of the judgment value is a method using the formula: [signal intensity from the nucleic acid probe for detecting a target nucleic acid] / ([signal intensity from the nucleic acid probe for detecting a target nucleic acid]+[signal intensity from the nucleic acid probe for detecting a non-target nucleic acid]).

[0118] Incidentally, the above-mentioned genetic mutation testing device is not limited to the above-mentioned configuration, and in order to prevent non-target nucleic acids in the nucleic acid amplification reaction solution from non-specifically hybridizing to the nucleic acid probe for detecting the target nucleic acid, a so-called blocking nucleic acid can also be used. The blocking nucleic acid can be mixed with a reaction solution containing a target nucleic acid and a non-target nucleic acid, and the resulting mixture can be brought into contact with a DNA chip to allow the hybridization reaction between the target nucleic acid and the nucleic acid probe for detecting the target nucleic acid to proceed. In addition, the reaction solution containing the target nucleic acid and the non-target nucleic acid and the solution containing the blocking nucleic acid can be mixed on the DNA chip to allow specific hybridization between the target nucleic acid and the nucleic acid probe to proceed simultaneously. In any of these cases, the blocking nucleic acid hybridizes to the non-target nucleic acid, thereby preventing the non-target nucleic acid from hybridizing to the probe for detecting the target nucleic acid.

[0119] The blocking nucleic acid has a base sequence complementary to a region containing a non-target base in the non-target nucleic acid, and can hybridize with the non-target nucleic acid containing the non-target base under conditions in which the target nucleic acid containing the target base can hybridize with the nucleic acid probe.

[0120] In the blocking nucleic acid, the position of the base corresponding to the non-detection target base is not particularly limited. The blocking nucleic acid is not particularly limited, but is preferably 60% or more in length relative to the base length of the nucleic acid probe. The blocking nucleic acid is preferably 140% or less in length relative to the base length of the nucleic acid probe. For example, if the length of the nucleic acid probe is 25 bases, the blocking nucleic acid is preferably 15 to 35 bases in length.

[0121] Furthermore, the blocking nucleic acid may contain mismatched bases (non-complementary bases) at positions corresponding to bases other than the non-detection target bases contained in the non-target nucleic acid. When the blocking nucleic acid is 15 bases long, the number of mismatched bases may be 1 to 3, preferably 1 to 2. When the blocking nucleic acid is 25 bases long, the number of mismatched bases may be 1 to 5, preferably 1 to 4.

[0122] Furthermore, the concentration of the blocking nucleic acid is not particularly limited, and can be appropriately set according to, for example, the concentration of the non-target nucleic acid and / or the concentration of the target nucleic acid, or according to the primer concentration. Specifically, the concentration of the blocking nucleic acid in the composition can be 0.01 to 2 μM, preferably 0.02 to 1.5 μM, and more preferably 0.05 to 1.5 μM.

[0123] In addition, when the blocking nucleic acid is used to prevent non-specific hybridization between the non-target nucleic acid and the nucleic acid probe for detecting the target nucleic acid, the specific hybridization between the non-target nucleic acid and the nucleic acid probe for detecting the non-target nucleic acid is also inhibited. In this case, the signal intensity from the nucleic acid probe for detecting the non-target nucleic acid is greatly reduced. In this case, the determination value according to the above formula: [signal intensity from the nucleic acid probe for detecting the target nucleic acid] / ([signal intensity from the nucleic acid probe for detecting the target nucleic acid]+[signal intensity from the nucleic acid probe for detecting the non-target nucleic acid]) may not be sufficient for quantitative analysis of the target nucleic acid. In this case, it is preferable to measure the total amount of the target nucleic acid and the non-target nucleic acid using a common probe.

[0124] As described above, the common probe has a sequence complementary to a common region common to the target nucleic acid and the non-target nucleic acid, and therefore can hybridize to the same non-target nucleic acid even if the blocking nucleic acid is hybridized to the same non-target nucleic acid.

[0125] When a common probe is used, the formula for calculating the above-mentioned judgment value can be [signal intensity from the nucleic acid probe for detecting the target nucleic acid] / [signal intensity from the common probe]. According to this formula, the influence of the blocking nucleic acid can be eliminated and the ratio of the target nucleic acid to the total of the target nucleic acid and non-target nucleic acid can be calculated.

[0126] In addition, the target nucleic acid can be absolutely quantified by preparing a calibration curve in advance. The calibration curve can be prepared by detecting the target nucleic acid and the non-target nucleic acid contained in the nucleic acid amplification reaction solution using various known mutation ratio samples (samples containing the target nucleic acid and the non-target nucleic acid at a known ratio), and calculating the determination value by the above formula. That is, the calibration curve shows the relationship between the determination value calculated as described above and the ratio of the target nucleic acid and the non-target nucleic acid contained in the nucleic acid amplification reaction solution, or the amount of the target nucleic acid.

[0127] As described above, the above-mentioned genetic mutation testing device can use nucleic acids recovered by the nucleic acid extraction device to quantitatively test whether genetic mutations are present in genomic DNA derived from a subject and the proportion of genetic mutations. EXAMPLES

[0128] The present invention will be described in more detail below with reference to examples, but the technical scope of the present invention is not limited to the following examples.

[0129] [Comparative Example 1] The nucleic acid extraction device (microchannel device) used in Comparative Example 1 is shown in FIG. 12. In FIG. 12, (A) is a top view of the nucleic acid extraction device, and (B) is a vertical cross-sectional view of the nucleic acid extraction device. The first substrate 101 of the microchannel device 100 shown in FIG. 12 uses ABS resin, and the recess is made by cutting processing, with external dimensions of 25.5×75×3 mm, the inlet channel 102 and the outlet channel 103 are 1.0 mm wide and 0.5 mm deep, and the reaction chamber 104 has a tapered shape that narrows toward the inlet channel 102 and the outlet channel 103, and the narrowing shape is 45° with respect to the liquid sending direction, and is 0.5 mm deep. The second substrate 105 is made of polyimide tape (3M #4390) using a cutting plotter (Graphtec Silhouette Cameo 4), with external dimensions of 25.5×75×0.13 mm, and internal dimensions are the same as the cut channel shape of the first substrate 101. The third substrate 106 was a COP film with external dimensions of 25.5×75×0.1 mm, and was produced by bonding the second substrate 105 with an adhesive applied to both sides of the second substrate 105. Particularly in this Comparative Example 1, the reaction chamber 104 was installed perpendicular to the direction of gravity.

[0130] In Comparative Example 1, as shown in Table 1, MagExtractor Genome manufactured by Toyobo was used as the extraction reagent, and HeLa cells were used as the template.

[0131] [Table 1]

[0132] Cell lysis, washing, and elution were performed by reciprocating (agitating) magnetic beads in the reaction chamber 104 from the inlet channel 102 to the outlet channel 103. The agitation was performed by operating a magnet 107 from the outside. The magnet was operated from the outside using a stirring device (ChipGenie Edition P manufactured by microfluidic ChipShop).

[0133] After the stirring was completed, the reagent was discharged from the outlet flow path 103, and the next reagent was injected from the inlet, and the same operation was repeated. The injection and ejection of the reagent was performed by pressurizing (discharging) air from the inlet flow path 102 side using a pump, or by depressurizing (suctioning) air from the outlet flow path 103 side using a pump.

[0134] In the stirrer, after the automatic stirring operation is completed, the magnet 107 returns to approximately the center in the longitudinal direction of the reaction chamber 104, so that the magnetic beads are gathered in the center of the reaction chamber 104 when the reagent is discharged.

[0135] The specific procedure for nucleic acid extraction is as follows. First, 10 μL of HeLa cells, 5 μL of magnetic beads, and 105 μL of lysis / adsorption solution were delivered from the inlet flow channel 102 and filled into the reaction chamber 104. The mixture was stirred for 10 minutes with the stirring device, and after the operation, the reagents other than the magnetic beads were discharged from the outlet flow channel 103. Next, 120 μL of washing solution was delivered from the inlet flow channel 102 and filled into the reaction chamber 104. The mixture was stirred for 1 minute with the stirring device, and after the operation, the reagents other than the magnetic beads were discharged from the outlet flow channel 103. The same operation using the washing solution was carried out a total of two times.

[0136] Next, 12 μL of 70% ethanol was delivered from the inlet flow channel 102 to fill the reaction chamber 104. The mixture was stirred for 1 minute with a stirrer, and after the operation was completed, the reagents other than the magnetic beads were discharged from the outlet flow channel 103. The same operation using ethanol was carried out twice in total.

[0137] Finally, 120 μL of purified water was delivered from the inlet flow channel 102 and filled into the reaction chamber 104. The mixture was stirred for 10 minutes with a stirrer, and after the operation was completed, the DNA eluate was collected from the outlet flow channel 103, leaving behind the magnetic beads. The nucleic acid concentration contained in the collected DNA eluate was quantified using a fluorometer (Thermo Fisher Scientific, Qubit).

[0138] Next, PCR was performed using the collected DNA, and the genetic mutation of the test subject was examined using a DNA chip. PCR was performed using primers (JAK2-F: SEQ ID NO: 1, JAK2-R: SEQ ID NO: 2) designed to amplify the JAK2 gene sequence shown in Table 2, and the reaction solution composition shown in Table 3. As a template, 40 ng of the extracted DNA was added.

[0139] [Table 2]

[0140] [Table 3]

[0141] The thermal cycle of PCR was 95° C. for 5 minutes, followed by 40 cycles of 95° C. for 30 seconds, 59° C. for 30 seconds, and 72° C. for 45 seconds, followed by 72° C. for 10 minutes, and finally maintaining at 4° C. Thirty microliters of the obtained PCR product was mixed with 15 μL of hybridization buffer (2.25×SSC / 0.23% SDS / 150 nM blocker) containing a blocker (JAK2 V617F blocker: CTCCACAGACACATACTC (SEQ ID NO: 3)) at room temperature without foaming, and hybridization reaction was carried out with a DNA chip (manufactured by Toyo Kohan Co., Ltd.) on which a probe (TTTTTTTTTTTTCTCCACAGACACATACTCC: SEQ ID NO: 4) having a sequence complementary to the wild type of the JAK2 gene was immobilized at 49.5° C. for 30 minutes. After the reaction, the DNA chip surface was immersed in a 0.1xSSC / 0.1%SDS solution at room temperature and shaken up and down 30 times to wash off excess PCR products from the DNA chip surface, then immersed in a 1xSSC solution at room temperature and shaken up and down 80 times in the same manner to rinse the DNA chip surface.

[0142] The rinsed DNA chip was then immersed in a glass container filled with 1xSSC solution at room temperature, and the fluorescence of the PCR product reacted on the chip surface was read by irradiating it with excitation light, and the fluorescence intensity was measured. The entire process from hybridization reaction to fluorescence detection was carried out using a genetic analyzer BIOSHOT HT-32 (manufactured by Toyo Kohan Co., Ltd.).

[0143] [Comparative Example 2] In Comparative Example 2, the same microchannel device as in Comparative Example 1 was used, and the nucleic acid extraction procedure was the same as in Comparative Example 1, except that when ejecting the reagent, the microchannel device was tilted so that the longitudinal direction of the reaction chamber was parallel to the direction of gravity (Figure 13).

[0144] In Comparative Example 2, the concentration of the recovered nucleic acid and the fluorescence intensity of the DNA chip were measured in the same manner as in Comparative Example 1.

[0145] [Example 1] In Example 1, the same microchannel device as in Comparative Example 1 was used, and the nucleic acid extraction procedure was the same as in Comparative Example 1, except that when ejecting the reagent, the microchannel device was tilted so that the longitudinal direction of the reaction chamber was parallel to the direction of gravity, and magnet 107 was positioned near the height of outlet channel 103, and magnetic beads were attracted to the tapered portion (Figure 14).

[0146] In Example 1 as well, the concentration of recovered nucleic acid and the fluorescence intensity of the DNA chip were measured in the same manner as in Comparative Example 1.

[0147] [Example 2] In Example 2, unlike Example 1 and Comparative Examples 1 and 2, a nucleic acid extraction apparatus 20 (vertical microchannel device) shown in Figs. 3 to 7 was fabricated and used.

[0148] In the vertical microchannel device used in this embodiment, a diaphragm valve 38A that can be opened and closed by pushing and pulling is installed downstream of the outlet channel 33 to prevent the reagent from being discharged from the chamber 4 due to gravity during stirring. In addition, downstream of the diaphragm valve 38A, a waste liquid recovery tank 30 for recovering unnecessary liquids (waste liquids) such as elution liquid and washing liquid, and a DNA recovery tank 29 for recovering DNA elution liquid are arranged.

[0149] The vertical microchannel device was made of ABS resin for the housing 22, with the recesses cut and fabricated, with external dimensions of 58×50×50 mm as viewed from the front, the inlets 2A and 2B and the outlet 3 having a width of 1.0 mm and a depth of 0.5 mm, and the chamber 4 having a tapered portion 13 whose narrowing shape is at an angle of 45° to the liquid feed direction, with a depth of 1.0 mm. The second substrate 23 was made of polyimide tape (3M #4390) using a cutting plotter (Graphtec Silhouette Cameo 4), with external dimensions of 30×50×0.13 mm as viewed from the front, and with internal dimensions the same as the cut channel shape of the surface portion of the housing 22 as viewed from the front. The third substrate 24 was made of COP film, with external dimensions of 30×50×0.1 mm as viewed from the front, and was fabricated by bonding both sides of the second substrate 23 together with an adhesive applied thereto. The housing 22 has a bottom flow path machined to be bonded to the fourth substrate 36 on the bottom surface, and the bottom flow path is 1.0 mm wide and 0.5 mm deep. A valve 38A is provided to prevent the reagent from flowing down when stirring in the chamber 4, and the valve 38A is 2.0 mm wide and 0.3 mm deep. The fourth substrate 36 is made of the same material and processed by the same method as the second substrate 23, and has an outer dimension of 58×50×50 mm as seen from the bottom surface, and an inner dimension of the fourth substrate 36 is the same as the bottom flow path shape of the housing 22. The fifth substrate 37 is made of silicon rubber, has an outer dimension of 58×50×0.5 mm as seen from the bottom surface, and is bonded to the fourth substrate 36 by an adhesive applied thereto.

[0150] Example 2 is similar to Comparative Example 1, except that in the nucleic acid extraction procedure using such a vertical microchannel device, the magnetic body 7 is positioned near the height of the outlet portion 3 when ejecting the reagent, and the magnetic beads are collected at the tapered portion 13.

[0151] In Example 2 as well, the concentration of recovered nucleic acid and the fluorescence intensity of the DNA chip were measured in the same manner as in Comparative Example 1.

[0152] [Results / Discussion] The results of measuring the concentrations of nucleic acids recovered in the above-mentioned Examples 1 and 2 and Comparative Examples 1 and 2 are shown in Fig. 15. Furthermore, the results of measuring the fluorescence intensity of the DNA chip in Examples 1 and 2 and Comparative Examples 1 and 2 are shown in Fig. 16.

[0153] As can be seen from Fig. 15, in the nucleic acid extraction procedure of Comparative Example 1, only a nucleic acid solution with an extremely low concentration could be recovered. In contrast, in the nucleic acid extraction procedure of Comparative Example 2, the reaction chamber 104 was tilted so that its longitudinal direction was parallel to the direction of gravity, and as a result, the nucleic acid recovery rate was improved. However, as in the nucleic acid extraction procedure of Example 1, the reaction chamber 104 was tilted so that its longitudinal direction was parallel to the direction of gravity, and magnetic beads were collected at the tapered portion, and as a result, a nucleic acid solution with a higher concentration could be recovered than in the procedure of Comparative Example 2.

[0154] Furthermore, in Example 2 using a vertical microchannel device, valve 38A prevents the elution solution filled in chamber 4 from flowing down, thereby enabling more reliable contact between the magnetic beads and the elution solution, and as a result, a nucleic acid solution with an extremely high concentration can be recovered.

[0155] 16, it was revealed that the nucleic acid extraction procedures of Examples 1 and 2 produced extremely high fluorescence intensity on the DNA chip compared to the nucleic acid extraction procedures of Comparative Examples 1 and 2. This is believed to be due to the fact that, although a relatively high concentration of nucleic acid solution can be recovered in the procedure of Comparative Example 2, impurities (such as ethanol) that inhibit the nucleic acid amplification reaction are mixed in. In contrast, it was revealed that the nucleic acid extraction procedures of Examples 1 and 2 produced a high purity nucleic acid solution, and as a result, excellent fluorescence intensity was observed.

Claims

1. a chamber having an inlet and an outlet, the inlet being located higher in the direction of gravity than the outlet and tapering toward the outlet, the chamber being loaded with magnetic beads capable of adsorbing nucleic acid; a magnetic bead control unit having a magnetic body that applies a magnetic force to the inside of the chamber and a drive unit that moves the magnetic body between the inlet and the outlet of the chamber; The nucleic acid extraction apparatus, wherein the magnetic bead control unit is capable of positioning the magnetic bodies at the tapered position in the chamber.

2. The nucleic acid extraction apparatus of claim 1, characterized in that the magnetic bead control unit stirs the solution filled in the chamber using the magnetic beads by moving the magnetic body between the inlet and outlet portions of the chamber using a drive unit while the chamber is filled with solution.

3. 2. The nucleic acid extraction apparatus according to claim 1, wherein the magnetic bead control unit positions the magnetic body at the tapered position in the chamber when passing liquid through the chamber from the inlet portion to the outlet portion.

4. 2. The nucleic acid extraction apparatus according to claim 1, further comprising an inlet channel and an outlet channel connected to the inlet and outlet portions of the chamber, respectively.

5. 5. The nucleic acid extraction apparatus according to claim 4, further comprising: a plurality of tanks connected to the outlet flow path; and a switching valve disposed in the outlet flow path for switching between and connecting the chamber to any one of the plurality of tanks.

6. 5. The nucleic acid extraction apparatus according to claim 4, further comprising: a first substrate on which the inlet flow path and a portion of the outlet flow path are formed; a second substrate and a third substrate which are combined with the first substrate to form the chamber; and a fourth substrate and a fifth substrate on which the remainder of the outlet flow path is formed and which are combined with the first substrate to form the entire outlet flow path.

7. 5. The nucleic acid extraction apparatus according to claim 4, further comprising a plurality of the inlet flow channels, and a plurality of reagent injection ports connected to the plurality of inlet flow channels.

8. A nucleic acid analyzer for analyzing nucleic acid extracted from a sample, comprising: An extraction unit comprising the nucleic acid extraction device according to any one of claims 1 to 7; A nucleic acid analyzer comprising an analysis unit connected to the extraction unit via a flow path and configured to analyze nucleic acids contained in the solution recovered by the nucleic acid extraction device.

9. The nucleic acid analysis apparatus according to claim 8, characterized in that the analysis unit includes a nucleic acid amplification unit that performs a nucleic acid amplification reaction using the nucleic acid contained in the solution recovered by the nucleic acid extraction device as a template, a hybridization unit that performs hybridization between the nucleic acid amplified in the nucleic acid amplification unit and a nucleic acid probe, and a detection unit that detects hybridization between the nucleic acid probe and the nucleic acid in the hybridization unit.

10. 10. The nucleic acid analyzer according to claim 9, wherein the hybridization section comprises a DNA chip.

11. The nucleic acid analysis apparatus according to claim 9, characterized in that the nucleic acid probes include a nucleic acid probe for detecting a target nucleic acid having a sequence complementary to a region including a target base to be detected in a target nucleic acid containing a base to be detected in a gene mutation, among the nucleic acids amplified in the nucleic acid amplification unit, and a nucleic acid probe for detecting a non-target nucleic acid having a sequence complementary to a region including a non-target base to be detected in a non-target nucleic acid containing a non-target base corresponding to the target base to be detected.

12. 10. The nucleic acid analyzer according to claim 9, wherein the analysis section quantitatively analyzes a target nucleic acid including a base to be detected in a gene mutation.

13. a chamber having an inlet and an outlet, the inlet being located higher in the direction of gravity than the outlet and tapering toward the outlet, and magnetic beads having nucleic acids adsorbed thereon being retained in the chamber, and a step of supplying an elution solution for eluting the nucleic acids from the magnetic beads into the chamber from the inlet; applying a magnetic force from outside the chamber to magnetically collect the magnetic beads at the tapered position; and discharging an eluate containing nucleic acid from the outlet port while magnetic beads are collected at the tapered position.

14. The nucleic acid extraction method according to claim 13, further comprising the steps of: supplying a solution containing a biological sample into the chamber from the inlet portion prior to the step of supplying the elution solution into the chamber; and then moving a magnetic body disposed outside the chamber between the inlet portion and the outlet portion to stir the solution with magnetic beads in the chamber, wherein nucleic acids derived from the biological sample are adsorbed onto the surface of the magnetic beads by this step.

15. The nucleic acid extraction method according to claim 14, further comprising a step of ejecting a solution from the outlet while the magnetic beads are magnetically collected at the tapered position after the nucleic acid derived from the biological sample is adsorbed onto the surface of the magnetic beads, and the solution ejected in this step and an eluate containing the nucleic acid are recovered in different tanks.

16. The nucleic acid extraction method according to claim 14, characterized in that the outlet portion and the multiple tanks are connected via an outlet flow path having a switching valve disposed therein, and the switching valve switches between connecting the chamber to any one of the multiple tanks.

Citation Information

Patent Citations

  • Multiple reaction chambers in the test cartridge

    JP2015516085A

  • Microchannel device

    WO2010061598A1

Cited By

  • Method and apparatus for testing gene mutations

    JP7943971B2

  • Testing method and testing device for genetic mutation

    JPWO2025089378A1

  • Testing method and testing device for genetic mutation

    WO2025089378A1